SAN DIEGO, Oct. 14, 2022 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) immediately introduced publication in the Cell Press journal Med of information detailing work referring to the invention and preclinical profiling of STI-9167 neutralizing antibody exercise in opposition to a broad assortment of SARS-CoV-2 variants, together with choose Omicron subvariants. Protection from Omicron-related illness in vivo in a preclinical problem mannequin was noticed following administration of STI-9167 by the intravenous (IV) route or following administration by the intranasal (IN) route utilizing an intranasal formulation of STI-9167 antibody, termed STI-9199.
A hyperlink to the publication will be discovered under:
https://www.cell.com/med/fulltext/S2666-6340(22)00321-X
About Sorrento Therapeutics, Inc.
Sorrento is a medical and business stage biopharmaceutical firm creating new therapies to deal with most cancers, ache (non-opioid therapies), autoimmune illness and COVID-19. Sorrento’s multimodal, multipronged method to combating most cancers is made attainable by its in depth immuno-oncology platforms, together with key belongings corresponding to next-generation tyrosine kinase inhibitors (“TKIs”), absolutely human antibodies (“G-MAB™ library”), immuno-cellular therapies (“DAR-T™”), antibody-drug conjugates (“ADCs”), and oncolytic virus (“Seprehvec™”). Sorrento can also be creating potential antiviral therapies and vaccines in opposition to coronaviruses, together with STI-1558, COVISHIELD™ and COVIDROPS™; and diagnostic take a look at options, together with COVIMARK™.
Sorrento’s dedication to life-enhancing therapies for sufferers can also be demonstrated by our effort to advance a (TRPV1 agonist) non-opioid ache administration small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a extensively used corticosteroid for epidural injections to deal with lumbosacral radicular ache, or sciatica, and to commercialize ZTlido® (lidocaine topical system) 1.8% for the therapy of postherpetic neuralgia (PHN). RTX has been cleared for a Phase II trial for intractable ache related to most cancers and a Phase II trial in osteoarthritis sufferers. Positive closing outcomes from the Phase III Pivotal Trial C.L.E.A.R. Program for SEMDEXA™, its novel, non-opioid product for the therapy of lumbosacral radicular ache (sciatica), had been introduced in March 2022. ZTlido® was authorized by the FDA on February 28, 2018.
For extra info go to www.sorrentotherapeutics.com
Forward-Looking Statements
This press launch and any statements made for and through any presentation or assembly include forward-looking statements associated to Sorrento Therapeutics, Inc., beneath the protected harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and topic to dangers and uncertainties that would trigger precise outcomes to vary materially from these projected. Forward-looking statements embody statements concerning the expectations for Sorrento’s and its subsidiaries’ applied sciences and product candidates. Risks and uncertainties that would trigger our precise outcomes to vary materially and adversely from these expressed in our forward-looking statements, embody, however usually are not restricted to: dangers associated to Sorrento’s and its subsidiaries’, associates’ and companions’ applied sciences and prospects and collaborations with companions; medical improvement dangers, together with dangers in the progress, timing, price, and outcomes of medical trials and product improvement packages; danger of difficulties or delays in acquiring regulatory approvals; dangers that medical research outcomes might not meet all or any endpoints of a medical research and that any information generated from such research might not help a regulatory submission or approval; dangers that prior take a look at, research and trial outcomes might not be replicated in persevering with or future research and trials; dangers of manufacturing and supplying drug product; dangers associated to leveraging the experience of its staff, subsidiaries, associates and companions to help Sorrento in the execution of its product candidates’ methods; dangers associated to the worldwide influence of COVID-19; and different dangers which might be described in Sorrento’s most up-to-date periodic reviews filed with the Securities and Exchange Commission, together with Sorrento’s Annual Report on Form 10-Ok for the 12 months ended December 31, 2021 and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, together with the danger components set forth in these filings. Investors are cautioned to not place undue reliance on these forward-looking statements, which communicate solely as of the date of this launch, and we undertake no obligation to replace any forward-looking assertion in this press launch besides as required by regulation.
Media and Investor Relations
Contact: Brian Cooley
Email: [email protected]
Sorrento® and the Sorrento emblem are registered emblems of Sorrento Therapeutics, Inc.
G-MAB™, DAR-T™, Seprehvec™, SOFUSA™, COVISHIELD™, COVIDROPS™, COVI-MSC™, COVIMARK™ and Fujovee™ are emblems of Sorrento Therapeutics, Inc.
SEMDEXA™ (SP-102) is a trademark of Semnur Pharmaceuticals, Inc. A proprietary title evaluation by the FDA is deliberate.
ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc.
All different emblems are the property of their respective homeowners.
©2022 Sorrento Therapeutics, Inc. All Rights Reserved.
